应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01276 恒瑞医药
交易中 12-29 13:30:58
71.500
+0.300
+0.42%
最高
72.500
最低
70.500
成交量
120.95万
今开
71.500
昨收
71.200
日振幅
2.81%
总市值
4,745亿
流通市值
184.47亿
总股本
66.37亿
成交额
8,612万
换手率
0.47%
流通股本
2.58亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
恒瑞医药(600276.SH)与翰森制药签署SHR6508项目独家许可协议
智通财经 · 12-28 16:43
恒瑞医药(600276.SH)与翰森制药签署SHR6508项目独家许可协议
创新药BD热后，估值“还债”中
药闻社 · 12-27 20:00
创新药BD热后，估值“还债”中
恒瑞医药：预计2026年3月26日公布年报，预测Q4一致预期营收320.72~360.62亿元
朝阳永续 · 12-26 19:01
恒瑞医药：预计2026年3月26日公布年报，预测Q4一致预期营收320.72~360.62亿元
智通AH统计|12月26日
智通财经网 · 12-26 16:15
智通AH统计|12月26日
长三角企业全球化路径：资本锚定全球，产业链扬帆远航｜2025中国经济年报
华夏时报网 · 12-25
长三角企业全球化路径：资本锚定全球，产业链扬帆远航｜2025中国经济年报
中国创新药“闯关”海外市场，如何实现全球价值兑现？
21世纪经济报道 · 12-25
中国创新药“闯关”海外市场，如何实现全球价值兑现？
国内商保发展和集采优化 创新药产业链持续活跃
金证研 · 12-24
国内商保发展和集采优化 创新药产业链持续活跃
恒瑞医药：SHR-A2102临床试验获批 聚焦实体瘤与食管癌
财中社 · 12-24
恒瑞医药：SHR-A2102临床试验获批 聚焦实体瘤与食管癌
恒瑞医药(600276.SH)：注射用SHR-A1904纳入突破性治疗品种名单
智通财经 · 12-24
恒瑞医药(600276.SH)：注射用SHR-A1904纳入突破性治疗品种名单
医药创新看中国：“一哥”恒瑞研发瞄定三大策略，构建全球竞争力
21世纪经济报道 · 12-23
医药创新看中国：“一哥”恒瑞研发瞄定三大策略，构建全球竞争力
HTI医药2025年12月第三周周报：行业高景气，持续关注创新药械产业链
海通国际 · 12-23
HTI医药2025年12月第三周周报：行业高景气，持续关注创新药械产业链
12月，石药集团、百济神州、百花村医药等一批药企已“换帅”
制药网 · 12-23
12月，石药集团、百济神州、百花村医药等一批药企已“换帅”
诺和诺德司美格鲁肽再下一城！心血管适应症在中国获批
制药网 · 12-23
诺和诺德司美格鲁肽再下一城！心血管适应症在中国获批
港股创新药概念股盘中拉升！石药集团涨超5%，荣昌生物涨超3%
老虎资讯综合 · 12-23
港股创新药概念股盘中拉升！石药集团涨超5%，荣昌生物涨超3%
医药生物行业跟踪周报：银屑病口服TYK2/IL23双雄并立格局确立 建议关注益方生物 诺诚健华 海思科等
东吴证券 · 12-23
医药生物行业跟踪周报：银屑病口服TYK2/IL23双雄并立格局确立 建议关注益方生物 诺诚健华 海思科等
每日卖空追踪 | 恒瑞医药 12月22日卖空量成交53.34万股，卖空比例为25.73%
市场透视 · 12-22
每日卖空追踪 | 恒瑞医药 12月22日卖空量成交53.34万股，卖空比例为25.73%
恒瑞医药：SHR-9539注射液获临床试验批准
南方财经网 · 12-19
恒瑞医药：SHR-9539注射液获临床试验批准
恒瑞医药12月18日遭主力抛售532.7万元
市场透视 · 12-18
恒瑞医药12月18日遭主力抛售532.7万元
诺和诺德：Wegovy®狂飙与9000人裁员背后的GLP-1赛道变局
摩熵医药 · 12-18
诺和诺德：Wegovy®狂飙与9000人裁员背后的GLP-1赛道变局
医药行业周报：年末国产创新药出海交易密集落地 2026年向上趋势中价值回归可期
交银国际 · 12-18
医药行业周报：年末国产创新药出海交易密集落地 2026年向上趋势中价值回归可期
加载更多
公司概况
公司名称：
恒瑞医药
所属市场：
SEHK
上市日期：
--
主营业务：
江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。
发行价格：
--
{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":71.5,"timestamp":1766986243860,"preClose":71.2,"halted":0,"volume":1209539,"delay":0,"floatShares":258000000,"shares":6637000000,"eps":1.1090831357612032,"marketStatus":"交易中","change":0.3,"latestTime":"12-29 13:30:58","open":71.5,"high":72.5,"low":70.5,"amount":86122689,"amplitude":0.02809,"askPrice":71.6,"askSize":4200,"bidPrice":71.45,"bidSize":3200,"shortable":3,"etf":0,"ttmEps":1.2867671267752339,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1766995800000},"marketStatusCode":2,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":71.2,"openAndCloseTimeList":[[1766971800000,1766980800000],[1766984400000,1766995200000]],"volumeRatio":0.56768,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":61,"timestamp":1766986256000,"preClose":61.06,"halted":0,"volume":18749200,"delay":0,"premium":"+5.68"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"2594822143","title":"恒瑞医药(600276.SH)与翰森制药签署SHR6508项目独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2594822143","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594822143?lang=zh_cn&edition=full","pubTime":"2025-12-28 16:43","pubTimestamp":1766911410,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 公告，公司与翰森制药集团有限公司签署《独家许可协议》，将公司SHR6508项目有偿许可给翰森制药;公司子公司成都盛迪医药有限公司与翰森制药子公司江苏豪森药业集团有限公司签署《商业化服务框架协议》，委托豪森药业为公司帕立骨化醇软胶囊产品提供非独家商业化服务。公司帕立骨化醇软胶囊于2025年11月获得国家药监局批准上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327494.USD","LU0405327148.USD","BK0060","LU2543165471.USD","LU1997244956.HKD","LU1255011170.USD","LU1023057109.AUD","BK0188","LU1328615791.USD","BK0183","LU2097828805.USD","BK0012","BK0239","LU2580892862.HKD","LU2148510915.USD","BK0028","LU1146622755.USD","BK1191","LU1820825898.SGD","LU1064130708.USD","LU2328871848.SGD","LU1655091616.SGD","03692","LU1064131003.USD","LU1997245177.USD","600276","LU0359202008.SGD","LU1969619763.USD","LU2488822045.USD","LU2097828631.EUR","LU2495084118.USD","LU1580142542.USD","LU2097828714.EUR","BK1583","LU2580892789.USD","01276","LU0359201885.HKD","LU2289578879.USD","LU1997245094.SGD","BK0196","LU0359201612.USD","LU2097828474.EUR","LU2097828557.USD","LU1781817850.SGD","BK1589"],"gpt_icon":0},{"id":"2594226457","title":"创新药BD热后，估值“还债”中","url":"https://stock-news.laohu8.com/highlight/detail?id=2594226457","media":"药闻社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594226457?lang=zh_cn&edition=full","pubTime":"2025-12-27 20:00","pubTimestamp":1766836823,"startTime":"0","endTime":"0","summary":"彼时，市面上甚至还有好几只年内收益翻倍的医药主题基金，BD交易频频刷屏，许多人都相信，“创新药的黄金十年”在二级市场上正在兑现。不少头部及腰部创新药企在年末连续发布了重磅的BD达成公告，交易对象不乏阿斯利康、武田、百时美施贵宝等全球制药巨头，但二级市场的反馈却时常冷淡，股价屡屡出现见光死的行情，市场情绪从期待转为疲软。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227200212a47ef53b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227200212a47ef53b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","01276","06978","BK1161","BK1574","01093"],"gpt_icon":0},{"id":"2594610296","title":"恒瑞医药：预计2026年3月26日公布年报，预测Q4一致预期营收320.72~360.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594610296","media":"朝阳永续","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594610296?lang=zh_cn&edition=full","pubTime":"2025-12-26 19:01","pubTimestamp":1766746860,"startTime":"0","endTime":"0","summary":"截至2025年12月26日，根据朝阳永续季度业绩前瞻数据：预测公司Q4一致预期营业收入320.72~360.62亿元，同比增长14.6%~28.9%；预测公司Q4一致预期净利润78.82~100.96亿元，同比增长24.4%~59.3%。在业务发展方面，恒瑞医药在对外授权合作上取得显著成果，与GSK、Glenmark和Braveheart_Bio等公司达成合作，涉及药物首付款总计5.83亿美元，里程碑付款最高可达141.16亿美元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-26/doc-inhecrxk0904902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01276","600276"],"gpt_icon":0},{"id":"2594622922","title":"智通AH统计|12月26日","url":"https://stock-news.laohu8.com/highlight/detail?id=2594622922","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594622922?lang=zh_cn&edition=full","pubTime":"2025-12-26 16:15","pubTimestamp":1766736905,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止12月26日收盘，东北电气、浙江世宝、钧达股份分列AH溢价率前三位，溢价率分别为900.00%、472.95%、286.59%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-11.39%、-3.20%、2.72%。其中浙江世宝、钧达股份、南京熊猫电子股份的偏离值位居前三，分别为187.01%、94.84%、36.09%；另外，广汽集团、长飞光纤光缆、北京北辰实业股份的偏离值位居后三，分别为-22.30%、-19.89%、-10.98%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0244354667.USD","LU0880133367.SGD","BK1514","LU0370786039.SGD","BK1583","CIHKY","LU0488056044.USD","LU1481107354.HKD","LU0516422366.SGD","LU0348814723.USD","SG9999014674.SGD","BK1240","LU2476274720.SGD","LU0572939691.SGD","LU0502904849.HKD","00553","600775","BK1173","BK1237","LU0096374516.USD","BK1568","LU1115378108.SGD","LU0140636845.USD","02865","LU1105468828.SGD","LU1831875114.USD","LU0269904917.USD","SG9999002463.SGD","LU2097828805.USD","BK1505","LU0181495838.USD","LU1242518931.SGD","LU0164880469.USD","LU0456846285.SGD","IE00BMCWC346.EUR","LU0469268626.HKD","LU0821914370.USD","LU0463099449.HKD","LU0561508036.HKD","BK1147","BK1521","BK1184","LU0052750758.USD","LU2097828474.EUR","LU1769817179.HKD","BK1594","LU0320764599.SGD","BK1231","LU2097828557.USD","LU0072913022.USD","LU0214875030.USD","LU0417516738.SGD","LU0918141887.USD","LU1211504680.USD","LU0314109678.HKD","LU0823426308.USD","LU0868486357.SGD","300750","LU2226246903.HKD","LU0039217434.USD","LU0254981946.USD","LU0823426480.USD","LU0384037296.USD","01276","LU1152091168.USD","03750","LU0456854461.SGD","LU0329678337.USD","LU0862451753.SGD","LU0516422440.USD","LU0054450605.USD","LU0348827113.USD","00042","BK1551","HK0000252160.HKD","LU0589944569.HKD","LU1770034418.SGD","LU0738912210.USD","LU0828238088.HKD","IE0034224299.USD","LU1188198961.HKD","BK1576","LU2242644610.SGD","IE00B29SXG58.USD","LU0348816934.USD","LU0918141705.HKD","LU1961090484.USD","BK1560","LU0315179316.USD","IE00BF5LJ272.USD","BK1154","BK1198","LU0149721374.USD","600036","HK0000306685.HKD","BK1149","HK0000500386.USD","LU1813983027.USD","IE00B3M56506.USD","LU2097828714.EUR","LU1688375341.USD","LU0327786744.USD","BK1535","LU0049853897.USD","HK0000252152.HKD","LU1719994722.HKD","LU0449515922.USD","LU0348788117.USD","BK1214","BK1506","LU1807302812.USD","LU1282649141.HKD","BK1183","BK1562","BK1141","IE00B031J352.USD","IE00BZ18W456.USD","LU0329678170.USD","LU0359201885.HKD","600276","BK1523","BK1507","BK1509","BK1163","LU0117841782.USD","IE00B543WZ88.USD","LU0572940350.SGD","IE00BYV24P56.USD","LU1794554557.SGD","HK0000320223.HKD","LU0106959298.USD","LU0593848301.USD","LU1282649067.USD","LU0359202008.SGD","BK1171","LU0061477393.USD","LU0231483743.USD","BK1550","LU0516423174.USD","LU0823040885.USD","BK1202","LU0455707207.USD","LU1366334578.USD","LU0264606111.USD","LU1880383366.USD","LU2476274308.USD","LU2045819591.USD","LU1808992512.USD","LU0516422952.EUR","LU0972618739.USD","LU0708995583.HKD","BK1116","IE00B031HY20.USD","SG9999006597.SGD","LU0737861772.HKD","LU0737861699.HKD","BK1567","LU1328277881.USD","LU0501845795.SGD","LU1366334651.USD","LU0348805143.USD","LU1008478684.HKD","LU0287142896.SGD","IE00BVYPNP33.GBP","LU0266512127.USD","BK1223","LU1023057109.AUD","LU0405327494.USD","LU1675838814.USD","LU0431992006.USD","LU0871576103.HKD","LU2125910500.SGD","LU1282648689.USD","LU0791590937.USD","LU2778985437.USD","601238","IE00BZ08YT58.USD","LU1960683339.HKD","LU0886674414.USD","IE00BGHQDM52.EUR","LU0328353924.USD","LU0307460666.USD","LU0516423091.SGD","LU0414403682.SGD","IE00BVYPNQ40.USD","LU0417516902.SGD","LU1224709979.USD","LU1226287529.USD","LU0828237940.HKD","LU2399975544.HKD","BK1129","BK1205","LU0173614495.USD","LU0348825331.USD","LU0531970944.HKD","LU1880383440.USD","SG9999002950.SGD","LU1152091754.HKD","LU0588546209.SGD","LU0051755006.USD","BK1206","601588","BK1554","HK0000320264.USD","BK1522","LU0345780281.USD","LU1046422090.SGD","SG9999002828.SGD","BK1539","BK1592","SG9999004220.SGD","IE00B0169L03.USD","LU0797268264.HKD","BK1558","LU2543165471.USD","IE0031814852.USD","LU0543330566.HKD","LU0359201612.USD","BK1144","BK1119","LU1303224171.USD","01057","LU0348735423.USD","LU1655091616.SGD","LU0164865239.USD","03143","IE0008369823.USD","BK1513","LU0449509016.USD","LU1282649810.SGD","00588","IE0008368742.USD","LU0540923850.HKD","LU0405327148.USD","LU1251922891.USD","BK1185","LU0345780521.USD","LU0634319403.HKD","BK1544","LU1242518857.USD","IE00BZ08YR35.GBP","LU1769817096.USD","IE00BZ18W340.USD","BK1610","LU0211977185.USD","LU0509642566.USD","LU0640798160.USD","LU0228659784.USD","LU0228367735.SGD","BK1191","LU1504937902.USD","LU0979878070.USD","002703","HK0000306701.USD","LU1048596156.SGD","LU2097828631.EUR","LU0266512473.USD","LU1993786604.SGD","02238","LU0828237510.HKD","IE00BMQBXF63.USD","LU0531971595.HKD","03968","601869","LU0456827905.SGD","LU1785774172.SGD","BK1546","LU0048580855.USD","LU0106252389.USD","LU0572944931.SGD","LU1720050803.USD","IE00BZ08YS42.EUR","BK1584","BK1564","LU0648948544.HKD","LU0229945570.USD","IE00B5MMRT66.SGD","LU0890818403.SGD","LU0326950275.SGD","LU0791591158.USD","LU0067412154.USD","LU2039709279.SGD","LU0163747925.USD"],"gpt_icon":1},{"id":"2594325830","title":"长三角企业全球化路径：资本锚定全球，产业链扬帆远航｜2025中国经济年报","url":"https://stock-news.laohu8.com/highlight/detail?id=2594325830","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594325830?lang=zh_cn&edition=full","pubTime":"2025-12-25 17:45","pubTimestamp":1766655927,"startTime":"0","endTime":"0","summary":"此次港股上市募资净额约20.96亿港元，其中25%专项用于扩展海外销售网络及市场推广。作为长三角G60科创走廊策源地，上海松江在2025年持续打造企业出海“母港”。长三角企业正以多元路径协同推进“品牌出海”，凭借扎实的产业基础优势和持续的技术创新能力，在全球市场中不断提升话语权。未来，随着长三角区域协同效应的进一步释放，持续推动从“中国制","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225181210a4772bbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225181210a4772bbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02676","LU0359201885.HKD","LU2543165471.USD","01276","LU0359202008.SGD","LU0359201612.USD","LU1023057109.AUD","BK1191","BK1163"],"gpt_icon":0},{"id":"2594928361","title":"中国创新药“闯关”海外市场，如何实现全球价值兑现？","url":"https://stock-news.laohu8.com/highlight/detail?id=2594928361","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594928361?lang=zh_cn&edition=full","pubTime":"2025-12-25 08:21","pubTimestamp":1766622108,"startTime":"0","endTime":"0","summary":"从长期来看，中国创新药市场规模有望持续增长，到2030年，中国创新药行业市场规模将接近2.3万亿元。完成审评5848个品种，同比增长9.49%；共计批准创新药上市54个品种。BD“造血”其实，2025年中国创新药行业最显著的特点，就是BD交易从“火热”到“价值兑现”的实质性跨越。这显示出中国创新资产在全球定价权的重要地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225082633a4751dd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225082633a4751dd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","BK1161","01801","01530","BK1574","01276","02615","06978"],"gpt_icon":0},{"id":"2593477930","title":"国内商保发展和集采优化 创新药产业链持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477930","media":"金证研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593477930?lang=zh_cn&edition=full","pubTime":"2025-12-24 21:11","pubTimestamp":1766581900,"startTime":"0","endTime":"0","summary":"随着国内商保发展和集采优化，创新药产业链高景气有望延续。当前支持创新药产业发展已成为政策导向，2025年北京、上海、重庆、四川等多地出台相关政策，推动创新药行业高质量发展。近日，2026年医保药品目录和商保药品目录发布，首次在基本医保目录之外增设商保创新药目录。创新药长期产业趋势确定，在国内政策支持以及美联储进入降息周期的背景下，全球创新药研发持续活跃，2026年还有大量BD落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224211713a6ca8bf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224211713a6ca8bf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348767384.USD","LU0634319403.HKD","LU2488822045.USD","LU2778985437.USD","LU0417516571.SGD","BK1161","LU1720050803.USD","01276","LU0561508036.HKD","01877","IE00BPRC5H50.USD","BK1574","09926","LU0348766576.USD","IE00B543WZ88.USD","LU2476274720.SGD","LU0348827113.USD","LU0540923850.HKD","LU2476274308.USD","01801","IE00B5MMRT66.SGD","06978","LU0348783233.USD","LU1961090484.USD","LU1794554557.SGD","ONC","LU0417516738.SGD","LU0348825331.USD","LU2399975544.HKD","LU0348735423.USD","LU0348784397.USD","LU0417516902.SGD"],"gpt_icon":0},{"id":"2593475884","title":"恒瑞医药：SHR-A2102临床试验获批 聚焦实体瘤与食管癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2593475884","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593475884?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:37","pubTimestamp":1766569070,"startTime":"0","endTime":"0","summary":"12月24日，恒瑞医药（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司近日获得国家药品监督管理局核准签发的关于注射用SHR-A2102的《药物临床试验批准通知书》，将于近期开展临床试验。该药物为公司自主研发的靶向Nectin-4的抗体药物偶联物，具有知识产权，其有效载荷是拓扑异构酶Ⅰ抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600814636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","LU2543165471.USD","BK0060","BK0188","BK0196","LU2580892789.USD","LU2097828805.USD","01276","LU2148510915.USD","LU0405327148.USD","LU0405327494.USD","LU2488822045.USD","LU2580892862.HKD","LU1328615791.USD","LU2097828714.EUR","LU2097828631.EUR","LU2289578879.USD","LU0359201885.HKD","LU1997244956.HKD","BK0239","LU1146622755.USD","LU2097828557.USD","LU1655091616.SGD","BK0183","LU1064130708.USD","LU1781817850.SGD","LU2495084118.USD","600276","LU1997245177.USD","LU2097828474.EUR","LU1023057109.AUD","LU1064131003.USD","BK0012","LU1580142542.USD","LU1255011170.USD","LU1997245094.SGD","LU0359202008.SGD","BK0028","LU1820825898.SGD","LU0359201612.USD","BK1191","LU2328871848.SGD"],"gpt_icon":1},{"id":"2593478682","title":"恒瑞医药(600276.SH)：注射用SHR-A1904纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2593478682","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593478682?lang=zh_cn&edition=full","pubTime":"2025-12-24 16:54","pubTimestamp":1766566481,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日,公司及子公司上海恒瑞医药有限公司注射用SHR-A1904被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。该药品拟定适应症(或功能主治)：既往接受至少一线系统治疗的CLDN18.2阳性的局部晚期或转移性胃或胃食管交界处腺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","LU2289578879.USD","LU1064130708.USD","LU2097828557.USD","LU2097828805.USD","LU2097828631.EUR","BK0012","LU0405327494.USD","LU2488822045.USD","LU2148510915.USD","LU0405327148.USD","LU1997245094.SGD","600276","01276","LU1580142542.USD","LU1781817850.SGD","LU1997245177.USD","LU2543165471.USD","BK0028","BK0196","LU1328615791.USD","BK0183","LU1969619763.USD","LU2097828714.EUR","LU2580892789.USD","LU1255011170.USD","BK0239","LU1146622755.USD","LU2097828474.EUR","LU1064131003.USD","BK0188","LU1820825898.SGD","LU1655091616.SGD","LU1997244956.HKD","LU2328871848.SGD","LU2580892862.HKD","LU2495084118.USD","LU0359201612.USD","LU1023057109.AUD","LU0359201885.HKD","BK0060","LU0359202008.SGD"],"gpt_icon":0},{"id":"2593419490","title":"医药创新看中国：“一哥”恒瑞研发瞄定三大策略，构建全球竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2593419490","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593419490?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:15","pubTimestamp":1766481352,"startTime":"0","endTime":"0","summary":"“中国在创新药研发管线方面的规模已占全球的四分之一左右，每年开展的临床试验数量约3000项，这两项关键指标均处于世界前列。”全球医药交易市场也在见证中国力量的崛起。而在创新队列中，恒瑞作为龙头企业，始终占据着重要位置。恒瑞医药董事长孙飘扬在2025年研发日上表示，恒瑞始终坚持创新与国际化战略。这些数据表明中国创新药正从“跟随式创新”迈向“全球领跑”的新阶段。一举创下国内史上BD单笔交易规模最大纪录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223172225a46e4c97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223172225a46e4c97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","01276","09939","BK1574","LU1023057109.AUD","LU2543165471.USD","BK1191","LU0359201612.USD","LU0359202008.SGD","BK1515","BK1161"],"gpt_icon":0},{"id":"2593494070","title":"HTI医药2025年12月第三周周报：行业高景气，持续关注创新药械产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2593494070","media":"海通国际","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593494070?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:07","pubTimestamp":1766477237,"startTime":"0","endTime":"0","summary":"2025年12月第三周A股医药板块表现与大盘相当。2025年12月第三周上证综指上涨0.03%，SW医药生物下跌0.1%，涨跌幅在申万一级行业中排名第19位。截至2025年12月19日，医药板块相对于全部A股的溢价水平目前处于正常水平，当前相对溢价率70.1%。2025年12月第三周美股标普医疗保健精选行业+0.6%，同期标普500+0.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223160731a6c4fe72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223160731a6c4fe72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","02615","BK1574","09606","01801","09939","BK1161","06990","02269","01858","BK1515","HK0000500386.USD","02359","01530","06160","01276","06078","HK0000252152.HKD","02487","HK0000252160.HKD"],"gpt_icon":0},{"id":"2593741940","title":"12月，石药集团、百济神州、百花村医药等一批药企已“换帅”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593741940","media":"制药网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593741940?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:17","pubTimestamp":1766474250,"startTime":"0","endTime":"0","summary":"如在近期，石药集团、百济神州、百花村医药等一批药企就已纷纷宣布“换帅”。12月19日，石药集团公告宣布执行董事蔡磊接任董事会副主席、首席执行官。12月12日，药明巨诺发布公告，宣布一系列核心管理层及董事会架构调整。除了上述企业，在12月以来，恒瑞医药、康恩贝、南新制药、振东制药等也已发布过高管变动公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223152053a46dc612&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223152053a46dc612&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YT58.USD","LU0307460666.USD","06160","IE0008369823.USD","LU1993786604.SGD","LU0880133367.SGD","LU0326950275.SGD","LU0359202008.SGD","BK1583","LU1328277881.USD","LU0315179316.USD","IE00BZ08YS42.EUR","BK1574","LU1008478684.HKD","LU1023057109.AUD","LU1813983027.USD","LU0588546209.SGD","LU1719994722.HKD","BK1588","LU0072913022.USD","LU1152091754.HKD","LU0067412154.USD","LU2039709279.SGD","IE00BZ08YR35.GBP","LU0314109678.HKD","LU0501845795.SGD","IE00B5MMRT66.SGD","LU1226288170.HKD","LU1951186391.HKD","LU1152091168.USD","HK0000165453.HKD","BK1161","LU0359201885.HKD","IE00B031HY20.USD","LU1960683339.HKD","BK1500","BK1191","01276","BK1515","LU2328871848.SGD","SG9999004220.SGD","LU1969619763.USD","IE00B543WZ88.USD","LU1226287529.USD","LU2543165471.USD","LU1807302812.USD","09939","LU0140636845.USD","01093","LU0359201612.USD"],"gpt_icon":0},{"id":"2593419495","title":"诺和诺德司美格鲁肽再下一城！心血管适应症在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2593419495","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593419495?lang=zh_cn&edition=full","pubTime":"2025-12-23 14:40","pubTimestamp":1766472046,"startTime":"0","endTime":"0","summary":"据悉，12月22日，诺和诺德方面披露，司美格鲁肽注射液的心血管适应症上市申请获得中国国家药品监督管理局批准上市。本次，诺和盈心血管适应症的获批，为医生和肥胖症患者提供了兼顾体重管理和心血管获益的有效治疗选择。业内表示，经随机对照试验和真实世界研究系统验证，司美格鲁肽在心血管获益方面具有坚实的循证证据，为肥胖及其合并症的治疗提供了全新策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223144303a46da61f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223144303a46da61f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","LU2543165471.USD","LU0359201885.HKD","LU0359202008.SGD","BK1191","01276","LU0359201612.USD"],"gpt_icon":1},{"id":"1130488131","title":"港股创新药概念股盘中拉升！石药集团涨超5%，荣昌生物涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130488131","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130488131?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:04","pubTimestamp":1766455472,"startTime":"0","endTime":"0","summary":"12月23日，港股创新药概念股盘中拉升，$石药集团(01093)$涨超5%，$恒瑞医药(01276)$、$三生制药(01530)$涨近3%，$先声药业(02096)$、$歌礼制药-B(01672)$、$康诺亚-B(02162)$涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"26e483f2c2080ad5ab71efdf30a08f1a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","01477","01530","06978","02096","02162","01672","01093"],"gpt_icon":0},{"id":"2593463647","title":"医药生物行业跟踪周报：银屑病口服TYK2/IL23双雄并立格局确立 建议关注益方生物 诺诚健华 海思科等","url":"https://stock-news.laohu8.com/highlight/detail?id=2593463647","media":"东吴证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593463647?lang=zh_cn&edition=full","pubTime":"2025-12-23 00:00","pubTimestamp":1766419200,"startTime":"0","endTime":"0","summary":"2025 年12 月18 日，济民可信集团宣布，其申报的2.2 类及2.4 类新药JMX-2005 注射液已获国家药品监督管理局批准开展临床试验。随着武田新一代TYK2 抑制剂Zasocitinib 三期临床阳性顶线数据的出炉，叠加强生口服IL23 受体拮抗剂Icotrokinra 关键三期研究数据的持续兑现，银屑病口服治疗领域TYK2/IL23 双雄并立的格局正式确立。建议关注在TYK2 赛道具备差异化竞争优势的公司：如益方生物、诺诚健华等，以及布局口服IL23 相关领域的公司：如海思科等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223071133a6c31d0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223071133a6c31d0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","09926","BK1161","01801","09969","BK1574","01276","02615"],"gpt_icon":0},{"id":"2593461483","title":"每日卖空追踪 | 恒瑞医药 12月22日卖空量成交53.34万股，卖空比例为25.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593461483","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593461483?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:30","pubTimestamp":1766392220,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间12月22日，跌0.28%，卖空量成交53.34万股，较上一交易日减少1.44%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163356a6c09ad8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163356a6c09ad8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","LU2543165471.USD","BK1191","LU0359202008.SGD","01276","LU0359201612.USD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2592157528","title":"恒瑞医药：SHR-9539注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592157528","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592157528?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:11","pubTimestamp":1766135494,"startTime":"0","endTime":"0","summary":"南财智讯12月19日电，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司及子公司苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司研发的SHR-9539注射液开展临床试验。审批结论显示，同意开展SHR-9539联合治疗在多发性骨髓瘤中的IB/II期研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193596828474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1781817850.SGD","LU2543165471.USD","BK1191","LU1255011170.USD","LU1655091616.SGD","BK0239","LU1820825898.SGD","LU2488822045.USD","LU1023057109.AUD","LU2289578879.USD","LU1969619763.USD","BK0012","LU2580892789.USD","LU2580892862.HKD","LU2495084118.USD","LU2097828805.USD","LU2148510915.USD","01276","LU1064131003.USD","LU2097828474.EUR","LU1997245177.USD","BK0183","600276","LU1328615791.USD","LU0405327494.USD","LU0405327148.USD","LU0359201612.USD","LU2097828557.USD","LU2097828714.EUR","LU1064130708.USD","LU2097828631.EUR","LU1146622755.USD","BK0028","BK0188","BK0060","LU2328871848.SGD","LU0359201885.HKD","LU1580142542.USD","LU1997245094.SGD","BK0196","LU1997244956.HKD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2592905538","title":"恒瑞医药12月18日遭主力抛售532.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592905538","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592905538?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:15","pubTimestamp":1766045745,"startTime":"0","endTime":"0","summary":"12月18日, 恒瑞医药股价跌0.84%，报收70.70元，成交金额1.1亿元，换手率0.61%，振幅2.66%，量比0.53。恒瑞医药今日主力资金净流出532.7万元，上一交易日主力净流出430.9万元。|12月18日主力加仓幅度排名||#|股票简称|主力净额占比|#|汇舸环保|1.86%|#|香江电器|1.25%|#|中国科创产业投资|0.96%|#|...|...|#2570|恒瑞医药|-0.03%|（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218162020a6b1a188&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218162020a6b1a188&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU0359202008.SGD","LU1023057109.AUD","LU2543165471.USD","LU0359201885.HKD","BK1191","01276"],"gpt_icon":0},{"id":"2592973957","title":"诺和诺德：Wegovy®狂飙与9000人裁员背后的GLP-1赛道变局","url":"https://stock-news.laohu8.com/highlight/detail?id=2592973957","media":"摩熵医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592973957?lang=zh_cn&edition=full","pubTime":"2025-12-18 11:07","pubTimestamp":1766027230,"startTime":"0","endTime":"0","summary":"2025年第三季度，诺和诺德的核心产品Wegovy销售额同比狂飙54%，但公司随之而来的决定却让很多人吃了一惊：全球裁员9000人。截至12月10日收盘，诺和诺德股价报收于49.05美元，较前一日上涨5.8%，市值重回2170亿美元以上。诺和诺德在美国的“高增长”依赖的是Wegovy的爆发式放量，而非整体产品线扩张。诺和诺德虽凭Wegovy实现高增长，却因技术代差、市场饱和与研发滞后被迫战略收。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218110738a4597356&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218110738a4597356&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","BK1161","LU2097828631.EUR","LU2488822045.USD","LU2242644610.SGD","LU2097828474.EUR","BK1589","LU2097828714.EUR","LU2097828805.USD","HK0000165453.HKD","03933","BK1583","01801","LU0455707207.USD","LU2097828557.USD","LU1969619763.USD","02196","01276","LU0502904849.HKD"],"gpt_icon":0},{"id":"2592490556","title":"医药行业周报：年末国产创新药出海交易密集落地 2026年向上趋势中价值回归可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2592490556","media":"交银国际","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592490556?lang=zh_cn&edition=full","pubTime":"2025-12-18 00:00","pubTimestamp":1765987200,"startTime":"0","endTime":"0","summary":"本周内资主要加仓龙头创新药企，包括恒瑞医药、荣昌生物和映恩生物；亦布局潜在受益于下游复苏的龙头CXO 企业，增持昭衍新药、晶泰控股和药明合联。投资启示：本周多项超10 亿美元的BD 交易相继落地，合作伙伴既有MNC也有中小型生物科技公司。临近年末，我们继续看好新BD 交易集中落地机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218192135a45b4ef9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218192135a45b4ef9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","BK1191","LU1023057109.AUD","BK1574","LU0359202008.SGD","LU2543165471.USD","BK1161","02192","06978","LU0359201885.HKD","01276"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.0223},{"period":"3month","weight":-0.2062},{"period":"6month","weight":0.2864},{"period":"1year","weight":0.6163},{"period":"ytd","weight":0.6163}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0251},{"period":"6month","weight":0.0632},{"period":"1year","weight":0.2846},{"period":"ytd","weight":0.2871}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}